Switch theme
Sign up to access all valuation multiples
Hong Kong Pharma Digital Technology Holdings Ltd operates in two main categories: (i) OTC pharmaceutical cross-border e-commerce supply chain services, conducted through its Hong Kong subsidiary, Joint Cross Border, which it refers to as the Supply Chain Services division, and (ii) OTC pharmaceutical cross-border procurement and distribution, conducted through its Hong Kong subsidiary, V-Alliance, which it referred to as the Procurement and Distribution division. Based in Hong Kong, Joint Cross Border has established itself as a provider of third-party supply chain services in Mainland China’s OTC pharmaceutical cross-border e-commerce market.
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Hong Kong Pharma has a last 12-month revenue of n/a and a last 12-month EBITDA of n/a.
In the most recent fiscal year, Hong Kong Pharma achieved revenue of $16.7M and an EBITDA of $2.5M.
Hong Kong Pharma expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Hong Kong Pharma valuation multiples based on analyst estimates| FY 2023 | FY 2024 | FY 2025 | LTM | NTM | |
|---|---|---|---|---|---|
| Revenue | $12.6M | $16.7M | XXX | XXX | XXX |
| Gross Profit | n/a | $2.7M | XXX | XXX | XXX |
| Gross Margin | NaN% | 16% | XXX | XXX | XXX |
| EBITDA | $1.8M | $2.5M | XXX | XXX | XXX |
| EBITDA Margin | 14% | 15% | XXX | XXX | XXX |
| Net Profit | n/a | $1.0M | XXX | XXX | XXX |
| Net Margin | NaN% | 6% | XXX | XXX | XXX |
| Net Debt | n/a | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of April 15, 2025, Hong Kong Pharma's stock price is $1.
Hong Kong Pharma has current market cap of $14.0M, and EV of $16.0M.
See Hong Kong Pharma trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $16.0M | $14.0M | XXX | XXX | XXX | XXX | n/a |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of April 15, 2025, Hong Kong Pharma has market cap of $14.0M and EV of $16.0M.
Hong Kong Pharma's trades at n/a LTM EV/Revenue multiple, and n/a LTM EBITDA.
Analysts estimate Hong Kong Pharma's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for Hong Kong Pharma and 10K+ public comps| FY 2024 | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|
| EV | $16.0M | XXX | XXX | XXX |
| EV/Revenue | 1.0x | XXX | XXX | XXX |
| EV/EBITDA | 6.3x | XXX | XXX | XXX |
| P/E | 10.5x | XXX | XXX | XXX |
| P/E/Growth | n/a | XXX | XXX | XXX |
| EV/FCF | -33.1x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpHong Kong Pharma's NTM/LTM revenue growth is n/a
Hong Kong Pharma's revenue per employee for the last fiscal year averaged n/a, while opex per employee averaged n/a for the same period.
Over next 12 months, Hong Kong Pharma's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate Hong Kong Pharma's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for Hong Kong Pharma and other 10K+ public comps| FY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|---|
| Revenue Growth | 33% | XXX | XXX | XXX | XXX |
| EBITDA Margin | 15% | XXX | XXX | XXX | XXX |
| EBITDA Growth | 44% | XXX | XXX | XXX | XXX |
| Rule of 40 (SaaS-only) | n/a | XXX | XXX | XXX | XXX |
| Revenue per Employee | n/a | XXX | XXX | XXX | XXX |
| Opex per Employee | n/a | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| Opex to Revenue | 11% | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| McMillan Shakespeare | XXX | XXX | XXX | XXX | XXX | XXX |
| Wipro | XXX | XXX | XXX | XXX | XXX | XXX |
| Alldigi Tech | XXX | XXX | XXX | XXX | XXX | XXX |
| R Systems | XXX | XXX | XXX | XXX | XXX | XXX |
| Firstsource Solutions | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Hong Kong Pharma acquired XXX companies to date.
Last acquisition by Hong Kong Pharma was XXXXXXXX, XXXXX XXXXX XXXXXX . Hong Kong Pharma acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign Up| When was Hong Kong Pharma founded? | Hong Kong Pharma was founded in 2023. |
| Where is Hong Kong Pharma headquartered? | Hong Kong Pharma is headquartered in United States of America. |
| Who is the CEO of Hong Kong Pharma? | Hong Kong Pharma's CEO is Mr. Lap Sun Wong. |
| Is Hong Kong Pharma publicy listed? | Yes, Hong Kong Pharma is a public company listed on NAS. |
| What is the stock symbol of Hong Kong Pharma? | Hong Kong Pharma trades under HKPD ticker. |
| When did Hong Kong Pharma go public? | Hong Kong Pharma went public in 2025. |
| Who are competitors of Hong Kong Pharma? | Similar companies to Hong Kong Pharma include e.g. McMillan Shakespeare, Wipro, Alldigi Tech, R Systems. |
| What is the current market cap of Hong Kong Pharma? | Hong Kong Pharma's current market cap is $14.0M |
| What is the current revenue growth of Hong Kong Pharma? | Hong Kong Pharma revenue growth between 2023 and 2024 was 33%. |
| Is Hong Kong Pharma profitable? | Yes, Hong Kong Pharma is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
